Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Anticuerpos Primarios

Anti-Human TDRKH Polyclonal Antibody (HP602014)

Precio(USD):
Especificación:
  • 50ug
  • 100ug
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHP602014
Descripción
Anti-Human TDRKH Polyclonal Antibody (HP602014) is a rabbit polyclonal antibody detecting TDRKH in ELISA, IHC, WB. Suitable for Human.
Highlights
  • ●Affinity Purified — Minimal background and high purity for reliable results.
  • ●Multi-Application — Validated across multiple applications.
Reactividad de especiesHuman, Mouse
AplicacionesELISA, IHC, WB
Especie huéspedRabbit
ClonalidadPolyclonal
IsotipoIgG
Inmunógeno E. coli - derived recombinant Human TDRKH (Ala30-Thr210).
Objetivo Tudor domain-containing protein 2, Tudor and KH domain-containing protein, TDRD2, TDRKH
Purificación Purified by antigen affinity column.
Número de acceso Q9Y2W6
Forma Liquid
Buffer de almacenamiento 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto
Aplicación Dilución
ELISA 1:5000-1:20000
IHC 1:50-1:500
WB 1:500-1:2000
Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fondo

Tudor and KH domain-containing protein (TDRKH) is a ~62 kDa protein. Participates in the primary piRNA biogenesis pathway and is required during spermatogenesis to repress transposable elements and prevent their mobilization, which is essential for the germline integrity. The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for the final steps of primary piRNA biogenesis by participating in the processing of 31-37 nt intermediates into mature piRNAs. May act in pi-bodies and piP-bodies by transferring piRNA precursors or intermediates to or between these granules.

Nota For research use only.
Imágenes
Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores